Pharmaceuticals company Wockhardt announced Q3FY26 results Financial Highlights: Revenue of Rs 888 crore in Q3FY26 compared to Rs 725 crore in Q3FY25 growth of 22%. EBITDA of Rs 173 crore compared to Rs 100 crore in Q3FY25, growth of 72%. Profit before tax Rs 67 crore for Q3FY26 as compared to Rs 21 crore in Q3FY25. Profit after tax Rs 61 crore against Rs 20 crore during Q3FY25. Business Highlights: India Branded Business stood at Rs 146 crore in Q3FY26 with a growth of 28% compared to the previous year. The India Business growth was aided by a substantial jump in our branded operations due to performance driven by the Diabetic therapy, NCE (EMROK), and the introduction of the Regenerative Derma segment. UK region stood at Rs 343 crore in Q3FY26 with a growth of 15% compared to the previous year. Emerging Markets region stood at Rs 264 crore in Q3FY26 with a growth of 48% compared to the previous year. The robust growth was driven mainly from our Biotech Insulin segment. The Latam operations contributed significant traction to the segment growth. Irish region stood at Rs 57 crore in Q3FY26 with a growth of 23% compared to the previous year. The overall Biotech operations for the quarter stood at Rs 213 crore, recording a growth of 96% vs Q4FY25 and 38% vs Q2FY26. This robust achievement is fuelled by our Emerging Market biotech segment growing at > 50 % with accelerated business opportunities and strategic business partnerships, new deal acquisitions from our key markets like Thailand, Egypt, Algeria and LATAM. Our Domestic Biotech operations continues to grow at double digit pace and is poised for decent growth in the future. Result PDF